However, when compared with 225Ac-PSMA-617, it suffers from higher perfusion-dependent off-target radiation, and a biological half-life of PSMA-617 in dose-limiting organs is longer than the physical half-life of 213Bi, making this agent a second-choice radiolabel for the targeted alpha therapy of PCa [129]. Here, FOLH1 is linked to posterior cortical atrophy.